Zydus Group aims two more novel drugs by 2020

10 Jun 2013 Evaluate

Zydus Cadila aims to launch at least two more novel drugs out of the 20 currently under discovery research programmes to become successful by 2020. It is currently working in the areas of metabolic disorders, oncology and inflammatory disorders. The company is planning to finance its drug discovery programmes, through internal resources.

A part of the Zydus Group, Cadila Healthcare had received regulatory approval to market its diabetes drug, Lipaglyn, in India last week. It expects the drug to be a blockbuster and clock over $1 billion sales a year when sold globally.

Zydus Lifesciences Share Price

1000.80 26.50 (2.72%)
14-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1768.75
Dr. Reddys Lab 1337.30
Cipla 1448.00
Lupin 2155.25
Zydus Lifesciences 1000.80
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.